Clinical Trial Update: A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial of daratumumab in relapsed or refractory Waldenström macroglobulinemia has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenström Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2021-04-22